Citations

Clear

1575 citation(s) found for "Im, Gene".

Orthopaedic Gene Therapy
Evans, Christopher H. , Ghivizzani, Steve, Robbins, Paul D. , Robbins, Paul D

Mayo Clinic

JBJS Reviews | August 26, 2021 | Volume: 9 | Issue: 8 | Pages: No page available

10.2106/jbjs.rvw.20.00220 | PMID 34437305 Get It

» Orthopaedics pioneered the expansion of gene therapy beyond its traditional scope of diseases that are caused by rare single-gene defects. Orthopaedic applications of gene therapy are most developed in the areas of arthritis and regenerative medicine, but several additional possibilities exist. » Invossa, an ex vivo gene therapeutic for osteoarthritis, was approved in South Korea in 2017, but its approval was retracted in 2019 and remains under appeal; a Phase-III clinical trial of Invossa has restarted in the U.S. » There are several additional clinical trials for osteoarthritis and rheumatoid arthritis that could lead to approved gene therapeutics for arthritis. » Bone-healing and cartilage repair are additional areas that are attracting considerable research; intervertebral disc degeneration and the healing of ligaments, tendons, and menisci are other applications of interest. Orthopaedic tumors, genetic diseases, and aseptic loosening are additional potential targets. » If successful, these endeavors will expand the scope of gene therapy from providing expensive medicines for a few patients to providing affordable medicines for many.
Intrarenal modulation of NF-κB activity attenuates cardiac injury in a swine model of CKD: a renal-cardio axis
Chade, Alejandro , Engel, Jason , Hall, Michael E. , Eirin, Alfonso , Bidwell, Gene L. , Chade, Alejandro R , Eirin, Alfonso

Mayo Clinic

American Journal of Physiology-Renal Physiology | August 16, 2021 | Volume: 321 | Issue: 4 | Pages: F411-F423

10.1152/ajprenal.00158.2021 | PMID 34396789 Get It

Chronic kidney disease (CKD) is a progressive disorder with high cardiovascular morbidity and mortality. This work supports the role of inflammatory cytokines of renal origin in renal-cardio pathophysiology in CKD and that the heart may be a target. Furthermore, it supports the feasibility of a new strategy in a translational fashion, using targeted inhibition of renal NF-κB signaling to offset the development of cardiac injury in CKD.
The evolving understanding of risk with calcitonin gene‐related peptide monoclonal antibodies based on real‐world data: A focus on hypertension and Raynaud phenomenon
Breen, Ilana, Mangold, Aaron R. , VanderPluym, Juliana H. , Breen, Ilana D, Mangold, A R , VanderPluym, Juliana

Mayo Clinic

Headache: The Journal of Head and Face Pain | August 7, 2021 | Volume: 61 | Issue: 8 | Pages: 1274-1276

10.1111/head.14198 | PMID 34364313 Get It

In Vitro and In Vivo Evaluation of Human Adenovirus Type 49 as a Vector for Therapeutic Applications
Bates, Emily A. , Counsell, John R. , Alizert, Sophie, Suff, Natalie , Boyle, Ashley K. , Bradshaw, Angela C., Waddington, Simon N. , Nicklin, Stuart A. , Baker, Andrew H. , Parker, Alan L. , Bradshaw, Angela C. , Baker, Alexander T. , Suff, Natalie , Boyle, Ashley , Waddington, Simon N , Nicklin, Stuart A , Baker, Andrew H , Parker, Alan L , Bates, Emily

Mayo Clinic

Viruses | July 28, 2021 | Volume: 13 | Issue: 8 | Pages: 1483

10.3390/v13081483 | PMID 34452348 Get It

The human adenovirus phylogenetic tree is split across seven species (A–G). Species D adenoviruses offer potential advantages for gene therapy applications, with low rates of pre-existing immunity detected across screened populations. However, many aspects of the basic virology of species D—such as their cellular tropism, receptor usage, and in vivo biodistribution profile—remain unknown. Here, we have characterized human adenovirus type 49 (HAdV-D49)—a relatively understudied species D member. We report that HAdV-D49 does not appear to use a single pathway to gain cell entry, but appears able to interact with various surface molecules for entry. As such, HAdV-D49 can transduce a broad range of cell types in vitro, with variable engagement of blood coagulation FX. Interestingly, when comparing in vivo biodistribution to adenovirus type 5, HAdV-D49 vectors show reduced liver targeting, whilst maintaining transduction of lung and spleen. Overall, this presents HAdV-D49 as a robust viral vector platform for ex vivo manipulation of human cells, and for in vivo applications where the therapeutic goal is to target the lung or gain access to immune cells in the spleen, whilst avoiding liver interactions, such as intravascular vaccine applications.
HER-2 Neu gene: A valuable therapeutic target in metastatic mucoepidermoid carcinoma
Mohammed, Turab , Mangeshkar, Shaunak , Desai, Aakash , Hegde, Upendra P. , Desai, Aakash P

Mayo Clinic

Journal of Oncology Pharmacy Practice | July 13, 2021 | Volume: 27 | Issue: 7 | Pages: 1806-1809

10.1177/10781552211032722 | PMID 34255585 Get It

Introduction Salivary gland neoplasms (SGNs) respond poorly to the traditional chemotherapy agents limiting the availability of systemic treatment options in the metastatic setting. The recent identification of actionable molecular targets in SGNs has led to the evaluation of targeted therapies in non-approved advanced SGNs. Case Report We present the case of an elderly male with HER-2 Neu overexpressing metastatic mucoepidermoid carcinoma (MEC) who demonstrated a prompt and sustained disease response to targeted therapies directed against HER-2 Neu with long survival interrupted by hepatoxicity to Trastuzumab emtansine (TDM-1) treatment. Management and Outcome: The patient was started on Trastuzumab and Pertuzumab on a clinical trial and resulted in an objective improvement sustained over 3 years. Following the disease progression, TDM-1 was started with a response until the patient developed severe hepatotoxicity as an adverse effect of TDM-1 therapy resulting in its discontinuation. Close follow-up post-treatment-discontinuation demonstrated continued clinical improvement until 6 months, when the patient developed brain metastasis. He passed away a few months later in hospice care. Discussion The metastatic MEC in our patient overexpressed HER-2 Neu. Owing to Trastuzumab and Pertuzumab response, Trastuzumab emtansine (TDM-1) was initiated on a compassionate basis which further extended the survival but had to be terminated owing to adverse effects. Given the paucity of data on targeted therapies in the treatment of metastatic SGNs and the safety, tolerability, and efficacy of TDM-1 therapy among the elderly, further studies are warranted to answer these important questions and to identify eligible patients for this novel treatment option.
COVID-19 Vaccines and Thrombosis—Roadblock or Dead-End Street?
Lundström, Kenneth , Barh, Debmalya , Uhal, Bruce D. , Takayama, Kazuo , Aljabali, Alaa A. A. , El‐Aziz, Tarek Mohamed Abd , Lal, Amos , Redwan, Elrashdy M. , Adadi, Parise , Chauhan, Gaurav , Azad, Gajendra Kumar , Rezaei, Nima , Serrano‐Aroca, Ángel , Hassan, Sk. Sarif , Panda, Pritam Kumar , Choudhury, Pabitra Pal , Pizzol, Damiano , Kandimalla, Ramesh , Baetas‐da‐Cruz, Wagner , Mishra, Yogendra Kumar , Palù, Giorgio , Brufsky, Adam , Tambuwala, Murtaza M. , Uversky, Vladimir N. , El-Aziz, Tarek M A , Azad, Gajendra Kumar , Rezaei, Nima , Serrano-Aroca, Ángel , Hassan, Sk Sarif , Panda, Pritam Kumar , Pizzol, Damiano , Kandimalla, Ramesh , Mishra, Yogendra Kumar , Brufsky, Adam M , Tambuwala, Murtaza , Uversky, Vladimir N , Adadi, Parise , Lal, Amos , Baetas-da-Cruz, Wagner , Aljabali, Alaa A A , Chauhan, Gaurav , Redwan, Elrashdy M , Barh, Debmalya , Takayama, Kazuo , Sherchan, Samendra , Bazán, Nicolás G.

Mayo Clinic

Biomolecules | July 13, 2021 | Volume: 11 | Issue: 7 | Pages: 1020

10.3390/biom11071020 | PMID 34356644 Get It

Two adenovirus-based vaccines, ChAdOx1 nCoV-19 and Ad26.COV2.S, and two mRNA-based vaccines, BNT162b2 and mRNA.1273, have been approved by the European Medicines Agency (EMA), and are invaluable in preventing and reducing the incidence of coronavirus disease-2019 (COVID-19). Recent reports have pointed to thrombosis with associated thrombocytopenia as an adverse effect occurring at a low frequency in some individuals after vaccination. The causes of such events may be related to SARS-CoV-2 spike protein interactions with different C-type lectin receptors, heparan sulfate proteoglycans (HSPGs) and the CD147 receptor, or to different soluble splice variants of the spike protein, adenovirus vector interactions with the CD46 receptor or platelet factor 4 antibodies. Similar findings have been reported for several viral diseases after vaccine administration. In addition, immunological mechanisms elicited by viral vectors related to cellular delivery could play a relevant role in individuals with certain genetic backgrounds. Although rare, the potential COVID-19 vaccine-induced immune thrombotic thrombocytopenia (VITT) requires immediate validation, especially in risk groups, such as the elderly, chronic smokers, and individuals with pre-existing incidences of thrombocytopenia; and if necessary, a reformulation of existing vaccines.
Abstract 344: Finding the Achilles’ heel of Muscle Giant---TALEN-mediated Gene-editing in Zebrafish Titin
Shih, Yu-Huan, Xu, Xiaolei

Mayo Clinic

Circulation Research | July 3, 2021 | Volume: 117 | Issue: suppl_1 | Pages: No page available

10.1161/res.117.suppl_1.344 Get It

Background: TITIN (TTN) has more than 300 exons and encodes a gigantic protein that is crucial for heart and muscle development. Mutations in TTN caused a variety of human diseases including cardiomyopathy and muscular dystrophy. Recently, dilated cardiomyopathy-associated mutations on TTN have been found more frequently in exons encoding A-band domains but less in exons encoding the N-terminal Z-disc domains, suggesting that mutations in different exons of TTN cause distinct consequences. To elucidate the underlying mechanisms, we leveraged the Transcription Activator-Like Effects Nuclease (TALEN) technology in zebrafish to introduce truncating mutations in different exons of ttn, and then study their effects on heart and somites. Results: We generated truncational mutations in different exons of zebrafish titins encoding Z-disc, N2B, Novex-3, and A domains, respectively. Because zebrafish contains two titin homologues, ttna and ttnb, we introduced mutations in both genes at the corresponding loci. While both Z-disc and A band mutations on ttna disrupted sarcomere assembly in heart and somites, Z-disc or A band mutations on ttnb only affect somites without affecting the heart. Interestingly, a Z-disc mutation on ttna resulted in milder phenotypes than an A-band mutation, while a Z-disc mutation on ttnb generated severer phenotypes than an A-band mutation. No phenotype was observed in the homozygous fish in either ttna-novex-3 or ttnb-N2B mutant fish. Conclusions: A spectrum of truncational mutations in ttna and ttnb has been generated in zebrafish using the TALEN technology. Mutations in different exons result in different phenotypes. Detailed characterization of these mutants and double mutants will be presented, which shall elicit distinct contribution of alternative splicing and exon skipping as two candidate mechanisms during pathogenesis of Titinopathies.
Abstract 3012: Significant Genome Wide Association Identified Between the Glycine N-Methyltransferase Gene (GNMT) and Post-Methionine Load Test Homocysteine Levels in the Vitamin Intervention for Stroke Prevention (VISP) Cohort
Chen, Fang , Keene, Keith L. , Chen, Wei‐Min , Hsu, Fang‐Chi , Wang, Liewei , Doheny, Kimberly F. , Zilka, Michelle, Worrall, Bradford B. , Sale, Michèle M. , Williams, Stephen R.

Mayo Clinic

Stroke | July 3, 2021 | Volume: 43 | Issue: suppl_1 | Pages: No page available

10.1161/str.43.suppl_1.a3012 Get It

The Vitamin Intervention for Stroke Prevention (VISP) trial was a multi-center, controlled, double blinded clinical trial, designed to determine whether the daily intake of high dose folic acid, vitamins B6 and B12 reduced recurrent cerebral infarction. Baseline post-methionine load homocysteine levels were predictive of recurrent stroke risk in VISP. We have conducted a genome-wide association study (GWAS), investigating 2100 VISP stroke cases required to have homocysteine levels greater than the 25th percentile at enrolment. Using imputation with 1000 genomes and principal component analysis, we were able to detect an association of p≤6.70x10-17 for SNPs within, or flanking, the glycine N-methyltransferase (GNMT) gene and post-methionine load test homocysteine level. Change in homocysteine levels pre and post-methionine load test also resulted in significant GWAS scores in the chromosome 6 region (p = 2.54x10-23, rs7760250). GNMT catalyzes the conversion of S-adenosyl-L-methionine to S-adenosyl-L-homocysteine and sarcosine via the folate one-carbon metabolism pathway. In addition to being an essential component in the conversion of methionine to homocysteine, GNMT plays a significant role in the global epigenetic state as homocysteine is an important methyl donor. This region displays significant linkage disequilibrium, warranting close analysis of the entire GNMT locus in search of both rare and common variants. Cases who carry the minor allele haplotype at associated loci had a higher level of post-methionine load homocysteine (37.69µM/L) than those who carry the major allele haplotype (27.33µM/L), inferring functional differences due to GNMT variants. Taken together these data suggest a clear and important role for GNMT in post-methionine load test homocysteine level, epigenetic state and stroke risk.
Abstract 108: TALEN-mediated Gene-Editing in Zebrafish for Studying Titin Biology
Shih, Yu-Huan, Xu, Xiaolei

Mayo Clinic

Circulation Research | July 3, 2021 | Volume: 113 | Issue: suppl_1 | Pages: No page available

10.1161/res.113.suppl_1.a108 Get It

Background: Titin, the largest protein found in nature, has been found to be crucial for heart and muscle development and mutations on titin caused human diseases. Especially, truncated mutations on TITIN were found to be a major causative gene (more than 25%) for familiar dilated cardiomyopathy (DCM) but the mechanism is lacking. Due to the gigantic size and number of exons, genetic study of titin has been challenging. To facilitate genetic analysis of titin biology, we leveraged the Transcription Activator-Like Effects Nuclease (TALEN) technology in zebrafish to edit the titin gene directly. Results: We generated TALEN pairs targeting different domains of zebrafish titin, including Z-disc domain, N2B domain, and A domains. Because zebrafish contain two titin homologues, ttna and ttnb , TALEN pairs targeting the corresponding loci for both homologues were made. The mutations are efficiently introduced on the titin using TALENs. In addition to these truncated mutants, TALEN technology can also create internal deletions. The titin mutant fish were identified and further phenotypic analysis has been carried out. Conclusions: Combined with TALEN technology, zebrafish can provide a convenient vertebrate model for genetic studies of titin biology. Moreover, this gene-editing technology will facilitate the use of the zebrafish model as a powerful research tool for modeling human diseases and investigating their pathogenesis.
The Role of Gene Therapy for Intimal Hyperplasia of Bypass Grafts
Cable, David G. , Caccitolo, James A., Simari, Robert D., Daly, Richard C. , Mullany, Charles J., Orszulak, Thomas A., Caplice, Noel M. , O’Brien, Timothy , Dearani, Joseph A. , Schaff, Hartzell V.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 100 | Issue: suppl_2 | Pages: No page available

10.1161/circ.100.suppl_2.ii-392 Get It

Background —Proliferation of the intima is an early lesion of saphenous vein graft disease. Early patency rates of radial artery grafts are acceptable, but little is known about their risk of intimal hyperplasia. Methods and Results —To develop a model of intimal hyperplasia, we incubated human saphenous veins, internal mammary arteries, and radial arteries (n=6, 8, and 10, respectively) in an organ culture with Rosewell Park Memorial Institute 1640 (30% serum) for 0, 4, 7, 10, and 14 days. Quantitative histological studies were performed, and the average intimal-to-medial (I/M) ratio was calculated for each incubation interval. After 10 and 14 days of culture, the I/M ratio increased in the saphenous veins ( P =0.03, P =0.04 versus 0 day, respectively). No significant increase occurred in the I/M ratio in either the internal mammary or radial arteries. Next, the ability of adenoviral gene transfers to inhibit intimal hyperplasia in the saphenous veins was evaluated. Adenoviral-mediated gene transfer of nitric oxide synthase significantly reduced the I/M ratio at 14 days compared with vehicle ( P =0.001) and virus ( P =0.004) controls. Conclusions —The human saphenous vein has a greater propensity for intimal hyperplasia than arterial grafts; the human radial artery behaves similarly to the internal mammary artery. In the future, gene therapy may augment nitric oxide synthase, limiting vein graft disease.